Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
